Analysts Offer Predictions for Kura Oncology Q3 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Brookline Capital Markets lifted their Q3 2026 EPS estimates for shares of Kura Oncology in a report issued on Wednesday, August 12th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of ($0.99) per share for the quarter, up from their previous estimate of ($1.06). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.30) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.48) EPS, FY2027 earnings at ($2.53) EPS, FY2028 earnings at ($2.36) EPS and FY2030 earnings at $17.13 EPS.

Several other equities research analysts have also recently commented on the company. Citizens Jmp restated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a report on Thursday, June 4th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Finally, Sanford C. Bernstein set a $24.00 price objective on Kura Oncology in a report on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.62.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $11.28 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -3.35 and a beta of 0.38. Kura Oncology has a one year low of $6.95 and a one year high of $12.49. The stock’s 50-day moving average is $10.27 and its 200-day moving average is $9.36.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The firm had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million.

Institutional Trading of Kura Oncology

A number of large investors have recently added to or reduced their stakes in KURA. Public Employees Retirement System of Ohio bought a new position in shares of Kura Oncology in the 2nd quarter valued at about $621,000. Corient Private Wealth LP acquired a new position in shares of Kura Oncology during the 2nd quarter worth about $1,344,000. Bank of America Corp DE bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $12,735,000. Man Group plc bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $4,749,000. Finally, Jupiter Topco LLC bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $273,000.

Insider Activity at Kura Oncology

In other news, CEO Troy Edward Wilson bought 100,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were acquired at an average cost of $11.12 per share, for a total transaction of $1,112,000.00. Following the completion of the acquisition, the chief executive officer owned 379,194 shares in the company, valued at approximately $4,216,637.28. This represents a 35.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares in the company, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.60% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.